# Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

> **NCT00393120** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 45 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** INCB009471
- **DRUG:** INCB009471
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT00393120
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393120, "Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00393120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*